CLAIMS

1. Use of Elafibranor in the manufacture of a medicament for the treatment of a cholestatic disease.

2. The use according to claim 1, wherein said Elafibranor is to be administered at a dose varying between 0.01 mg and 1 g per administration, preferentially from 1 mg to 150 mg per administration, and more preferably from 70 mg to 130 mg.

3. The use according to claim 1 or 2, wherein said Elafibranor is in the form of a pharmaceutical composition.

4. The use according to claim 3, wherein said composition is formulated in the form of injectable suspensions, gels, oils, pills, suppositories, powders, gel caps, capsules, aerosols or means of galenic forms or devices assuring a prolonged and/or slow release.

5. The use according to any one of the preceding claims, wherein the cholestatic disease is selected in the group consisting of Primary Biliary Cholangitis (PBC), Primary Sclerosing Cholangitis (PSC), Intrahepatic Cholestasis of Pregnancy, Progressive Familial Intrahepatic Cholestasis, Biliary atresia, Cholelithiasis, Infectious Cholangitis, Cholangitis associated with Langerhans cell histiocytosis, Alagille syndrome, Nonsyndromic ductal paucity, Drug-induced cholestasis, and Total parenteral nutrition – associated cholestasis.

6. The use according to claim 5, wherein the cholestatic disease is PBC or PSC.

7. The use according to claim 6, wherein the cholestatic disease is PBC.

8. The use according to any one of claims 1 to 7, wherein said Elafibranor is to be orally administered once daily at a dose of 80 or 120 mg/day, in particular to a patient with PBC with inadequate response to UDCA.

9. The use according to any one of claims 1 to 8, wherein said Elafibranor is to be administered in combination with another anti-cholestatic agent.